論文・技術情報追加のお知らせ

1. Global large-scale real-world assessment of drug-associated galactorrhea based on FDA adverse drug reaction reports.

FAERS解析で薬剤性乳汁漏出症の高リスク薬を同定

対象DB：FAERS

2. Ocular adverse reactions associated with intraocular pressure-reducing drugs: An analysis of the FDA adverse event reporting system (FAERS).

眼圧下降薬による眼障害をFAERSで包括評価

対象DB：FAERS

3. Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems.

VAERSを用いた米国ワクチン安全性監視の現状

対象DB：FAERS,VAERS

4. Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system.

アザチオプリン関連妊娠性肝内胆汁うっ滞の検討

対象DB：FAERS,KAERS

5. Assessment of drug induced thyroid dysfunction risk using the FDA adverse event reporting system (FAERS).

FAERSによる薬剤性甲状腺機能異常の網羅的解析

対象DB：FAERS

6. Drug-Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real-World Retrospective Study.

モキシフロキサシン関連薬物性肝障害の評価

対象DB：FAERS

7. Disproportionality Analysis of Adverse Events Associated with IL-1 Inhibitors in the FDA Adverse Event Reporting System (FAERS).

IL-1阻害薬の有害事象シグナルを不均衡解析

対象DB：FAERS

8. Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database.

DPP-4阻害薬と水疱性類天疱瘡の関連解析

対象DB：EudraVigilance,FAERS

9. The guanylate cyclase stimulator vericiguat: Insights and adverse events from a FAERS-based pharmacovigilance study.

ベルイシグアトの実臨床有害事象プロファイル

対象DB：FAERS

10. Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD((R))) reported to the vaccine adverse event reporting system (VAERS), 2015-2025.

MMRVワクチン接種後有害事象のVAERS解析

対象DB：FAERS,VAERS

11. A 20-year FAERS analysis of hypersensitivity reports to chlorhexidine and povidone-iodine (2004-2024).

CHXとポビドンヨード過敏症報告を20年FAERS解析

対象DB：FAERS

12. Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system.

FAERSを用い、うつ病治療薬の有害事象シグナルを網羅的に解析

対象DB：FAERS

13. Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study.

睡眠薬による有害事象を実臨床データで比較評価した研究

対象DB：FAERS

14. Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system.

CDK4/6阻害薬の毒性プロファイルを薬剤別に比較解析

対象DB：FAERS

15. A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system data.

ロフルミラスト関連有害事象をFAERSで検出した研究

対象DB：FAERS

16. Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS).

ヘッジホッグ阻害薬と特定有害事象の関連を検討

対象DB：FAERS

17. A real-world pharmacovigilance study of modafinil events in the FDA Adverse Event Reporting System (FAERS).

モダフィニルの安全性を実世界データで評価

対象DB：FAERS

18. Melanosis Secondary to Drugs: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

薬剤性メラノーシスの特徴を薬剤疫学的に解析

対象DB：FAERS

19. Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system.

ドネペジルの有害事象を包括的に評価した研究

対象DB：FAERS

20. Adverse Events Reported Following RSV Prefusion F Protein Vaccines Administration Among Approved Populations: A Cross-Sectional Study.

RSV予防抗体投与後の有害事象をVAERSで解析

対象DB：FAERS,VAERS

21. Machine learning prediction of pediatric adverse drug reactions using consensus-derived scarce data.

小児薬剤有害事象を機械学習で予測する研究

対象DB：FAERS

22. Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS).

神経系薬剤による先天異常をFAERSで網羅的に解析

対象DB：FAERS

23. Isotretinoin-related adverse sexual and reproductive outcomes: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).

イソトレチノインの性・生殖系有害事象をFAERSで評価

対象DB：FAERS

24. Skin Injuries Following Layperson Application of Chemical Peel Products.

一般人による医薬品使用後の皮膚損傷を実態調査

対象DB：FAERS

25. Drug-Induced Intestinal Angioedema: A Disproportionality Analysis Using the United States Food and Drug Administration Adverse Event Reporting System Database and Literature Review.

薬剤性腸管血管性浮腫の安全性シグナルを検出

対象DB：FAERS

26. Estimating risk of reported versus theoretical drug-drug interactions in headaches medicine: an exhaustive comparison between DrugBank and FAERS database for abortive and preventive combinations.

片頭痛治療薬併用時の理論的リスクと実報告を比較

対象DB：FAERS

27. Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database.

GLP-1受容体作動薬と眼障害の関連をFAERSで解析

対象DB：FAERS

28. A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals.

エスケタミン有害事象と薬物相互作用をFAERS解析

対象DB：FAERS

29. Itraconazole-associated adverse events in fungal infections: a study of a large real-world sample based on the FAERS database (2019-2024).

イトラコナゾールの心・肝障害など新規安全性シグナル検出

対象DB：FAERS

30. Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference.

バリシチニブ副作用は年齢差があり、血栓など早期発症に注意

対象DB：FAERS

31. Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis.

前立腺癌治療のADTは薬剤ごとに心血管リスクが異なる

対象DB：FAERS

32. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.

有害事象DBの低質研究が誤った安全警告を生む問題を指摘

対象DB：FAERS

33. Real-world data of verteporfin-related ocular adverse events: A disproportionality analysis.

ベルテポルフィンで多数の新規眼科副作用シグナル検出

対象DB：FAERS

34. Adverse event reporting of mirtazapine: A disproportionality analysis of FDA adverse event reporting system (FAERS) database from 2004-2024.

ミルタザピンで未報告含む多様な副作用、初期1か月に多発

対象DB：FAERS

35. Calcitonin gene-related peptide antagonists in Raynaud's phenomenon: a disproportionality study based on real data and drug-gene network analysis.

CGRP拮抗薬でレイノー現象のリスクと機序を示唆

対象DB：FAERS

36. Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

タゼメトスタットは初期に新規副作用シグナル多く注意

対象DB：FAERS

37. Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system.

新規テトラサイクリン系は消化管障害が多く早期発症

対象DB：FAERS

38. Fedratinib in chronic kidney disease: antifibrotic potential and renal safety signals from integrated network toxicology and pharmacovigilance.

フェドラチニブは腎線維化抑制の可能性と腎障害・B1欠乏リスクを併せ持つ

対象DB：FAERS

39. Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.

テポチニブは治療初期に副作用多く、新規安全性シグナルも確認

対象DB：FAERS

40. Fluoroquinolone-Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real-World Data From FAERS (2011-2024).

フルオロキノロンは精神・眼障害と関連し、特にモキシフロキサシンで眼毒性顕著

対象DB：FAERS

41. Analysis of age-specific adverse events with vancomycin: a real-world pharmacovigilance study based on the FAERS database.

バンコマイシン副作用は年齢別に特徴が異なり新規シグナルも検出

対象DB：FAERS

42. Exploration of the associations between violent and aggressive behaviors risk and NHHR, TyG in patients with schizophrenia: an SHAP interpretable machine learning prediction and FAERS pharmacovigilance analysis.

統合失調症の暴力リスクに脂質指標が関連し予測可能

対象DB：FAERS

43. Signal stratification of antineoplastic drugs associated with interstitial lung disease: A multi-method signal detection analysis using the FAERS database.

抗がん薬関連ILDは薬剤差大、特に分子標的薬で強い信号

対象DB：FAERS

44. A real-world pharmacovigilance study of FDA adverse event reporting system events for cefazolin.

セファゾリンで重篤アレルギー等の安全性シグナル検出

対象DB：FAERS

45. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib.

フィルゴチニブで未記載副作用含む多様な安全性シグナル検出

対象DB：FAERS

46. Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.

GLP-1作動薬は注射部位反応が増え、特に一部薬剤で顕著

対象DB：FAERS

47. Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system.

抗がん薬の心毒性は薬剤別に様式と発症時期が異なる

対象DB：FAERS

48. Real-world pharmacovigilance insights into drug-induced risk of alopecia.

多薬剤で脱毛リスクを確認、抗がん薬で強く性差や発症時期差あり

対象DB：FAERS

49. Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.

CAR-T/TCE治療で稀な致死的IEC-HS、特定製剤で報告増加

対象DB：FAERS

50. Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database.

メサラジン副作用は早期発症が多く、男性や併用薬が不耐症リスク

対象DB：JADER

51. Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

難治性てんかん補助薬は薬剤別に副作用傾向が異なり注意が必要

対象DB：EudraVigilance

52. Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase.

クリゾチニブは早期発症の眼障害と強く関連

対象DB：VigiBase

53. Alice in wonderland syndrome: Down the rabbit hole of VigiBase(R).

薬剤関連AIWSは年齢差があり、モンテルカスト等で報告多い

対象DB：VigiBase

54. Clozapine and Suicide in VigiBase: Most Important Fatal Outcome in Young Males and Differences Between Attempted and Completed Suicide.

クロザピン治療中の若年男性で自殺死亡が多く、服薬継続が重要

対象DB：VigiBase

55. Artificial intelligence in oncology drug development and management: a precision medicine perspective.

AIががん薬開発から市販後安全性評価まで革新をもたらす

対象DB：VigiBase

56. Cost and clinical outcomes of transoral robotic surgery versus radiation therapy for T1-2N0-1M0 pharyngeal and laryngeal cancers.

頭頸部癌でロボット手術は放射線治療より低コスト・短期入院

対象DB：DPC

57. Temporal trends in the prescription of traditional Japanese herbal (Kampo) medicines to pregnant women: analysis of an administrative hospital database in Japan.

妊婦への漢方処方は増加傾向で当帰芍薬散が最多

対象DB：DPC

58. Tracking Day Shift Nurses' Work Patterns Using an Indoor Positioning System in an Internal Medicine Ward at a Japanese University Hospital.

位置情報で看護業務を可視化、平日は人員多く効率的対応

対象DB：DPC

59. Explainable machine learning for predicting postoperative length of stay after gastrectomy: a nationwide study using XGBoost and SHAP.

胃切除後在院日数を機械学習で高精度予測可能

対象DB：DPC

60. Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine.

RA患者のPCPは免疫抑制で増え、SASPに予防効果の可能性

対象DB：DPC

61. Epidemiology and Prognostic Factors of Herpes Simplex Virus Encephalitis in Japan: A Nationwide Database Study.

単純ヘルペス脳炎は死亡6％、生存者に重い後遺障害多い

対象DB：DPC

62. Synergistic effects of underweight and dementia on in-hospital mortality during acute myocardial infarction.

AMI患者で低体重と認知症併存は院内死亡を相乗的に増加

対象DB：DPC

63. Prevalence and incidence of Coats disease in a large claims database.

コーツ病は小児で有病・発症率が成人の約2倍、男性優位

対象DB：JMDC

64. Association between dispensing regulations for extended-release methylphenidate and prescription trends in Japan: an exploratory descriptive study.

ADHD薬の流通規制で処方増加が鈍化、特に20歳未満で顕著

対象DB：NDB

65. Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.

膀胱癌周術期化学療法は増加し、患者・施設要因で差がある

対象DB：MDV

66. Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD.

COPD初回重症増悪を高精度に予測するモデル開発

対象DB：CPRD

67. Antibiotics and preterm delivery: The prevalent new-user cohort design to resolve immortal time bias.

妊娠後期の抗菌薬使用は早産リスクをわずかに増加

対象DB：CPRD

68. Health inequalities and trends in heart failure diagnosis in primary care in England, 2000-21: a national retrospective cohort data-linkage study.

英一次診療の心不全診断、検査不足で格差拡大

対象DB：CPRD

69. Disparities in uptake of Shingrix(R) vaccine in immunosuppressed individuals in England: a population-based cohort study.

免疫抑制高齢者で帯状疱疹ワクチン接種率が低く格差顕著

対象DB：CPRD

70. Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, and risperidone in severe mental illness: a target trial emulation.

アリピプラゾール単剤は他剤と比べ、長期心血管リスクは同等

対象DB：CPRD

71. Quantifying the health-care burden of temperature in the National Health Service in England: an economic analysis of resource use and costs.

寒さで受診・入院・死亡増、高齢者中心にNHS医療費約3%影響

対象DB：CPRD

72. Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.

高齢2型糖尿病でSGLT2阻害薬は認知症リスク低下

対象DB：CPRD

73. Comparative effectiveness and safety of herbal medicine therapy for low back pain and radiculopathy caused by lumbar intervertebral disc herniation: a study protocol for a pragmatic randomized controlled trial.

腰椎椎間板ヘルニアに対する韓方薬治療の有効性・安全性を検証

対象DB：KAERS

74. Sex differences in the progression of cardiovascular-kidney-metabolic syndrome.

CKM進行に伴う心血管疾患リスクと性差の検討

対象DB：DeSC